Clinical Trials

GastrointestinalGynecologic

199 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05111561 2026-03-17

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Phase 1 Suspended

42 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04221438 2026-03-12

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

3 enrolled 11 charts

Lymphatic Metastasis, Melanoma

NCT05926960 2026-03-09

PORTSIDE

38 enrolled

Melanoma, Skin Neoplasms

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

1 enrolled

Phase EARLY_PHASE1 Recruiting

Anatomic Stage IV Breast Cancer AJCC v8

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

50 enrolled

921 enrolled 48 charts 1 FDA

Melanoma

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT03170206 2026-02-12

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

34 enrolled

Phase EARLY_PHASE1 Active not recruiting

Lung Neoplasms

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

14 enrolled

CNSDermatologicHead & NeckThoracic

Melanoma, Skin Neoplasms

NCT05355701 2026-02-03

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

267 enrolled

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

336 enrolled

DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT05286788 2026-01-12

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

38 enrolled

CNS

Craniopharyngioma

NCT04585815 2026-01-09

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1/2 Terminated

34 enrolled 44 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05195632 2026-01-07

OCEANII

63 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 1/2 Active not recruiting

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03991819 2025-12-05

BiniPembro

Phase 1 Recruiting

40 enrolled

Non-small Cell Carcinoma

NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

75 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04061980 2025-11-19

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

24 enrolled

Head & Neck

Thyroid Neoplasms

NCT04439344 2025-11-19

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

LymphoidOther hematologic neoplasmPlasma cell

53 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04526782 2025-11-18

ENCO-BRAF

119 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04324112 2025-11-10

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Other hematologic neoplasm

45 enrolled

Leukemia, Hairy Cell

NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Phase 1 Terminated

65 enrolled 52 charts

CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT04892017 2025-10-10

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1/2 Active not recruiting

144 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02285439 2025-10-07

Study of MEK162 for Children With Low-Grade Gliomas

105 enrolled 17 charts

CNS

Brain Neoplasms, Soft Tissue Neoplasms

NCT06887088 2025-10-01

ENCEFALO

33 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04598009 2025-09-03

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

25 enrolled

Melanoma

NCT04322383 2025-08-26

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Other hematologic neoplasm

40 enrolled

Leukemia, Hairy Cell

NCT02185690 2025-08-21

MEK162

13 enrolled 11 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07022457 2025-08-03

UK-EnBiRiM

Recruiting

50 enrolled

Melanoma

NCT03235245 2025-08-01

EBIN

271 enrolled

Phase 4 Not yet recruiting

Melanoma

NCT07092410 2025-07-29

SuRage-EB

101 enrolled

Melanoma

NCT05304546 2025-07-22

MK3475-C01

1 enrolled

Melanoma, Neoplasms

NCT03106415 2025-06-27

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

23 enrolled 14 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03898908 2025-05-21

EBRAIN-MEL

48 enrolled 24 charts

CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT03231306 2025-05-02

NF108-BINI

45 enrolled 8 charts

CNS

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

NCT03971409 2025-05-02

InCITe

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Other solid neoplasmThoracic

58 enrolled

Solid Tumor

NCT04735068 2025-04-01

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05340621 2025-03-07

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

36 enrolled

Melanoma

NCT04375527 2024-12-04

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

3 enrolled

Melanoma

NCT03374254 2024-11-21

KEYNOTE-651

116 enrolled 18 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03973918 2024-10-31

BRAF

CNSGastrointestinalThoracic

5 enrolled 15 charts

CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

53 enrolled

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT03475004 2024-09-19

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

53 enrolled 14 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04965818 2024-09-19

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Phase 1 Terminated

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05810740 2024-09-19

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

37 enrolled 25 charts